Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | C1S | P09871 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213532 | 0.84 | PARP1 (0.54) | PARP1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL5211059 | 0.81 | NPC1 (0.49) | MAPTMEN1KMT2AL3MBTL1GAA | |
| SCHEMBL241785 | 0.73 | PARP1 (0.68) | PARP1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL30153175 | 0.73 | PARP1 (0.68) | PARP1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL1093916 | 0.72 | NPC1 (0.49) | MAPTTSHRMAPK1ALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL27869733 | 0.71 | PARP1 (0.65) | PARP1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL6885327 | 0.70 | PARP1 (0.50) | PARP1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL3838580 | 0.69 | PARP1 (0.63) | PARP1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL19530988 | 0.69 | LMNA (0.63) | PARP1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL29088630 | 0.69 | PARP1 (0.58) | PARP1MAPTMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653952-A4 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2007-04-04 | — | — | EP | claimed |
| US-7112599-B2 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2006-09-26 | — | — | US | claimed |
| EP-1653952-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005016267-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-20050032859-A1 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2005-02-10 | — | — | US | claimed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| EP-1653952-A4 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7112599-B2 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1653952-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016267-A2 | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050032859-A1 | Oxazole compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032859-A1 | Oxazole compounds for the treatment of neurodegenerative disorders | APP, OXA1L, BACE1 | PARP1 2997/4885MAPT 63/4885MEN1 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.